Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study-Reference-Cited by-同舟云学术

Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study

Published:2013-12-06 Issue:4 Volume:31 Page:399-402
ISSN:0742-3071
Container-title:Diabetic Medicine
language:en
Short-container-title:Diabet. Med.

Author:

Ambery P.¹,Donner T. W.²,Biswas N.¹,Donaldson J.¹,Parkin J.¹,Dayan C. M.³

Affiliation:

1. GlaxoSmithKline; Uxbridge UK

2. Division of Endocrinology; Johns Hopkins University School of Medicine; Baltimore MD USA

3. Diabetes Research Group; Institute of Molecular and Experimental Medicine; Cardiff University School of Medicine; Cardiff UK

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dme.12361/fullpdf

Reference7 articles.

1. CD3-specific antibody-induced active tolerance: from bench to bedside;Chatenoud;Nat Rev Immunol,2003

2. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass;Keymeulen;Diabetologia,2010

3. Partial and transient modulation of the CD3-T-cell receptor complex, elicited by low-dose regimens of monoclonal anti-CD3, is sufficient to induce disease remission in non-obese diabetic mice;Mehta;Immunology,2010

4. GlaxoSmithKline and Tolerx announce phase III DEFEND-1 study of otelixizumab in type 1 diabetes did not meet its primary endpoint http://us.gsk.com/html/media

5. http://clinicaltrials.gov/show/NCT00678886

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapies for Type 1 Diabetes;Textbook of Diabetes;2024-01-12

2. C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis;The Lancet Diabetes & Endocrinology;2023-12

3. Baseline plasma proinsulin response to glucose for predicting therapeutic response to otelixizumab in recent-onset type 1 diabetes;Diabetes Research and Clinical Practice;2023-11

4. Disease-modifying therapies and features linked to treatment response in type 1 diabetes prevention: a systematic review;Communications Medicine;2023-10-05

5. Anti-CD3 monoclonal antibodies in treatment of type 1 diabetes: a systematic review and meta-analysis;Endocrine;2023-09-01